Anzeige
Mehr »
Login
Freitag, 11.10.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Drei Millionen Unzen und steigend: NexGold Minings Rennen um die Vorherrschaft in der Mid-Tier-Liga
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
258 Leser
Artikel bewerten:
(0)

DNotes Global, Inc.: DNotes Global Inc. Launches Reg. D 506 (C) Funding to Raise $5 Million from Accredited Investors in a Series of Three Funding Rounds

DNotes Global, Inc. announced its first funding round utilizing Reg. D 506 (c) to raise $5 million from accredited investors is now live. An offering statement has been filed with the SEC and a Private Placement Memorandum (PPM) is now available to verified accredited investors. Prospective investors must be verified through the company's investor web portal: https://investors.dnotesglobal.com

CHICAGO, IL / ACCESSWIRE / July 12, 2018 / DNotes Global, Inc. announced on Thursday that its first funding round utilizing Reg. D 506 (c) to raise $5 million from accredited investors is now live. An offering statement has been filed with the SEC and a Private Placement Memorandum (PPM) is now available to verified accredited investors. Prospective investors must first be verified through the company's investor web portal: https://investors.dnotesglobal.com.

Regulation D Rule 506 (c) was created as part of the JOBS Act to facilitate capital formation and job creation in 2012 (Jumpstart Our Business Startups Act). This funding program is only available to accredited verified investors.

An accredited investor, in the United States, must have a net worth of at least $1,000,000, excluding the value of his or her primary residence, or have an annual income of at least $200,000 for the last two years (or $300,000 combined income if married).

$5,000,000 offering

Up to 1,000,000 Class A Common Shares of DNotes Global, Inc. representing 12.5% ownership on a fully diluted basis of the outstanding shares are offered with a minimum subscription of $5,000 (5 units).

DNotes Global's founder and CEO Alan Yong confirmed that this is the first of three funding rounds in the company's relentless effort to propel DNotes digital currency toward mass adoption as an inclusive, trusted digital currency for global commerce. He explained that this is a massive global project that started with the launch of DNotes on Feb. 18, 2014. The company is already actively working on a second funding round that will utilize Reg. A+ Mini-IPO Tier 2 to raise up to $50 million from accredited and non-accredited investors worldwide. Yong also indicated that the third round will involve a traditional IPO, with the participation of underwriters.

DNotes Global had previously committed to seeking funding through these more traditional, regulated avenues, rather than using an initial coin offering (ICO), as many other crypto-related projects have done in recent years. Yong said that he has yet to see an ICO that complies with current legal requirements and reaffirmed his company's commitment to working with regulators as DNotes Global raises the capital it needs to continue its mission of achieving mass adoption for the DNotes digital currency.

"I believe that digital currency and its underpinning blockchain technology is a generational opportunity that will be even bigger than the Internet," Yong said. "As it moves toward mass adoption, it will result in massive job and wealth creation for people everywhere."

Yong vowed that his company would continue to provide the type of leadership the digital currency industry needs to ensure that the technology's benefits are enjoyed by as many people around the world as possible. He cited the company's innovative ecosystem, services, and the 25% pre-dilution shares gifted to the currency as part of the cross-ownership model as clear examples of how DNotes Global plans to increase inclusivity and accessibility. His goal is simple: to make sure that no one gets left behind in the digital currency revolution.

"Inclusiveness rests at the heart of everything that we do," Yong insisted. "The DNotes team understands that digital currency needs to be accessible and inclusive for everyone - and that means that we need to work to remove barriers that might otherwise inhibit participation. As we have developed the DNotes ecosystem, we have endeavored to make everything as easy to use as possible to ensure maximum accessibility."

Whether it is our innovative CRISP savings plans, making DNotes proof-of-stake, or our DNotes Pay automated payment system, inclusivity is always one of our primary concerns. For digital currency to fulfill its promise to the world, it must be accessible, trustworthy, and inclusive."

About DNotes and Alan Yong:

DNotes co-founder Alan Yong is a well-regarded visionary who established Dauphin Technology in 1988. He is the author of the book "Improve Your Odds: The Four Pillars of Business Success and is well-regarded as a "thought leader" in the cryptocurrency industry.

DNotes is a digital currency noted for its consistent and reliable growth, and innovative initiatives that actively engage women, young people, small businesses, workers, and others - effectively inviting the world to participate in the digital currency revolution.

For more information please visit: https://investors.dnotesglobal.com

To view the DNotes white paper, please visit: https://dnotesglobal.com/white-paper

Media contact

Name: Alan Yong
Email: media@dnotesglobal.com

SOURCE: DNotes Global, Inc.

© 2018 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.